Frederik Peeters retweeted
🎙️ New #ESMO Podcast – Controversies in Upper GI Cancers
📌 Radiotherapy in borderline resectable #PDAC:
Evidence vs practice – when does it make sense?
@NiuSanford & @BasGrootKoerkam join me to discuss a case & key trials.
🎧 Listen: open.spotify.com/episode/6NF…
#PancreaticCancer
Frederik Peeters retweeted
🎧 New @myESMO upper GI podcast!
We unpack key #ASCO25 updates in #PancreaticCancer & #BiliaryCancer:
✔️ CASSANDRA
✔️ PANOVA-3
✔️ Elraglusib
✔️ GAIN & POLCA-GB
w/ @ArndtVogel & Florian Castet
🎙 Listen: open.spotify.com/episode/47u…
#GIonc
Frederik Peeters retweeted
Excited to share our new study published in JNCI! 🧬
In >500 real-world BTC pts treated with cisplatin, gemcitabine & durvalumab, we found:
✔️ SMAD4 mut = better outcomes
❌ TP53 & TERT mut = worse survival
🔬 A new clinico-molecular score for patients
academic.oup.com/jnci/advanc…
Frederik Peeters retweeted
It was an honour to host the @EASLedu Basic Science School at the TGLU Oxford @TGU_Oxford @NDMOxford with a brilliant keynote from @druppygill and lots of hands on learning in the lab. Great to connect with delegates from across the world @DavidTrampert @DraMartaAlonsoP
Frederik Peeters retweeted
🔬 our last study on #BTC patients
Our findings reveal key clinical and molecular factors linked to maintenance #immunotherapy with #durvalumab in advanced BTC. These insights could guide better patient selection and personalized treatments.
onlinelibrary.wiley.com/doi/…
Frederik Peeters retweeted
Five-year OS update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
@JHepatology
doi.org/10.1016/j.jhep.2025.…
👉OS rate at 5 yrs: 19.6% vs 9.4%
🧐Interesting OS data for pts w/ disease control & any degree of tumour shrinkage
@myESMO @EASLedu @ILCAnews
Frederik Peeters retweeted
Cell by cell, we shall unravel the contribution of components in patients with #HCC treated with atezo/bev… journal-of-hepatology.eu/art…
Frederik Peeters retweeted
Original Article
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy
Scheiner et al.
#LiverX
journals.lww.com/hep/abstrac…
Frederik Peeters retweeted
Clinical and molecular variables associated with early progression to checkpoint inhibitors in MSI-high metastatic colorectal cancer: a retrospective cohort study.
clinical-colorectal-cancer.c…
Frederik Peeters retweeted
🔥 ASCO 2024 Plenary: Prof Dr @JDekervel (UZ Leuven) and Prof Dr @FlorianLordick (University of Leipzig) discuss the ESOPEC trial, comparing FLOT perioperative chemotherapy with neoadjuvant chemoradiotherapy for adenocarcinoma of the oesophagus or oesophagogastric junction.
Frederik Peeters retweeted
Baanbrekende studie TRANSMET toont het aan: patiënten met uitgezaaide dikkedarmkanker naar de lever kunnen geholpen worden met een #levertransplantatie. "Voor jongere kankerpatiënten met een levertumor uit de darm betekent dit de kans op een nieuw leven."
bit.ly/3XdKNzF
Frederik Peeters retweeted
NIVO + IPI vs LEN (90%) or SORA as 1st line treatment for HCC #ASCO24
🤩Exciting times: More & more options in 1st line HCC
💪Clear improvement in OS with ICI based therapy & sequential therapy
🎯Now, we need biomarkers to guide treatment decisions
@myESMO @ILCA @EASL #livertwitter
Frederik Peeters retweeted
Last weekend, a CCB delegation cycled the #1000km of @komop_tgkanker 🚴🚴
Together with 1250 other teams, they managed to collect almost 7M EUR to support cancer research!
Amazing effort, amazing team 🤩
Thank you Bram, Shauni, Isabelle, Lars, Alexandra, Frederik en Amelie!
Frederik Peeters retweeted
Check out our #openaccess review on single-cell omics for liver cancer research including nice figures (by @PeetersFre) and an overview table of all previous efforts! @JHEP_Reports
🟪NEW Article in press❕
Applications of single-cell multi-omics in liver cancer
🔓#OpenAccess at 👉jhep-reports.eu/article/S258…
#LiverTwitter
#HepatocellularCarcinoma
#HCC
Frederik Peeters retweeted
Special issue of #COPHAR on GI cancer is finally complete
Overview 👉 authors.elsevier.com/a/1iehg…
🙏 @AngelicaSSophie for editing
🙏 all contributors - @jcloydmd, @michele_ghidini, @IreneChong6, @RonaYaeger, @FedericaPapacc1, @PeetersFre and many others!!
Frederik Peeters retweeted
Tissue is the issue, also in #HCC ❗️
Radiological diagnosis of HCC does not preclude biopsy before treatment
@JHEP_Reports
doi.org/10.1016/j.jhepr.2023…
🔎167 pts
👉50% of poorly differentiated HCC not classified as LR-5
👉11% of LR-5 cases misqualified, incl. CRC & BTC cases
🧐Biopsy is 🗝️in the era of precision medicine
@myESMO @EASLnews @ILCAnews #livertwitter
Frederik Peeters retweeted
Leuvense onderzoekers keken met single cell technologie tot op het diepste niveau van de cellen in de tumor en vonden een #biomerker die kan voorspellen of een patiënt met #leverkanker zal reageren op #immuuntherapie of niet. 🔬
Meer weten? 👉bit.ly/41UHxcK
Frederik Peeters retweeted
📢📢 PAPER OUT !!
🤔What biology underlies response to #atezobev in #HCC ?
🔬scRNA and scTCR sequencing of tumour and blood samples
🔜tweetorial of the amazing @CappuynsSarah
🙏Fruitful collaboration with @LambrechtsDlab
👀#OpenAccess Paper is here: rdcu.be/dshsE
Frederik Peeters retweeted
🌟 October is #LiverCancerAwarenessMonth, a time to shed light on the various types of liver cancers. 🌟
Liver cancers originate in different liver cells, and understanding them is crucial for early detection and treatment. Knowing these types and their unique characteristics is a step towards early diagnosis and better outcomes.
Share this information to raise awareness and save lives! 💚
easl.eu/news/lcam23/
@EASLEUAffairs @dice_europe @EuropeLiver @ILCAnews